NASDAQ:RDHL RedHill Biopharma (RDHL) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free RDHL Stock Alerts $0.46 +0.01 (+2.21%) (As of 05/24/2024 ET) Add Compare Share Share Today's Range$0.46▼$0.4750-Day Range$0.38▼$0.5552-Week Range$0.26▼$3.28Volume107,887 shsAverage Volume249,465 shsMarket Capitalization$13.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get RedHill Biopharma alerts: Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About RedHill Biopharma Stock (NASDAQ:RDHL)RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.Read More RDHL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RDHL Stock News HeadlinesMay 22, 2024 | uk.finance.yahoo.comPensioners win £9,000 back in 16-year council tax battleMay 20, 2024 | americanbankingnews.comRedHill Biopharma (NASDAQ:RDHL) Receives New Coverage from Analysts at StockNews.comMay 7, 2024 | finanznachrichten.deRedHill Biopharma Ltd.: RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035May 6, 2024 | prnewswire.comRedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035April 24, 2024 | finance.yahoo.comRedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 StudyApril 10, 2024 | finance.yahoo.comRedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022)April 9, 2024 | bizjournals.comRaleigh pharma weighs divesting commercial operationsApril 8, 2024 | finanznachrichten.deRedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2023 Results and Operational HighlightsApril 8, 2024 | finance.yahoo.comRedHill Biopharma Ltd. (2RH0.F)April 8, 2024 | prnewswire.comRedHill Biopharma Announces Full-Year 2023 Results and Operational HighlightsApril 2, 2024 | finance.yahoo.comRedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market PriceMarch 11, 2024 | markets.businessinsider.comRedHill Biopharma Receives New Patent For H. Pylori Treatment TaliciaMarch 11, 2024 | finance.yahoo.comRedHill Announces New USPTO Patent Covering Talicia® Through 2034March 5, 2024 | finance.yahoo.comRedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures ProgramsFebruary 20, 2024 | finance.yahoo.comRedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New PublicationFebruary 20, 2024 | prnewswire.comRedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New PublicationFebruary 16, 2024 | barrons.comRedHill Biopharma Ltd. ADRJanuary 26, 2024 | finance.yahoo.comRedHill Biopharma Announces Closing of $8 Million Registered Direct OfferingJanuary 25, 2024 | msn.comRedHill gains after new patent grant for Talicia for H. pylori treatment through 2042January 25, 2024 | finance.yahoo.comRedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042January 25, 2024 | finance.yahoo.comRedHill Biopharma Announces $8 Million Registered Direct OfferingJanuary 24, 2024 | benzinga.comWhy Redhill Biopharma Stock Is Moving HigherDecember 20, 2023 | msn.comRedHill's Investigational COVID-19 Drugs Combined With Gilead's Show Effect Against EbolaDecember 20, 2023 | markets.businessinsider.comRedHill Announces Results Of A New U.S. Army-funded In Vivo Ebola Virus StudyDecember 20, 2023 | msn.comRedHill shares rally 20% on positive data for two antiviral drugsSee More Headlines Receive RDHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/30/2021Today5/26/2024Next Earnings (Estimated)6/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RDHL CUSIPN/A CIK1553846 Webwww.redhillbio.com Phone972-3541-3131Fax972-3541-3144Employees53Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.84 Quick Ratio0.61 Sales & Book Value Annual Sales$6.53 million Price / Sales2.10 Cash Flow$1.32 per share Price / Cash Flow0.35 Book Value$0.11 per share Price / Book4.21Miscellaneous Outstanding Shares29,700,000Free Float27,680,000Market Cap$13.75 million OptionableNo Data Beta3.47 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Dror Ben-Asher (Age 58)Co-Founder, Chairman & CEO Comp: $594.61kMr. Razi Ingber (Age 40)Chief Financial Officer Comp: $339.82kMr. Gilead Raday MPhil (Age 49)MSc, Chief Operating Officer Comp: $365.56kMr. Adi Frish (Age 54)Chief Corporate & Business Development Officer Comp: $339.3kMr. Rick D. Scruggs (Age 64)Chief Commercial Officer, President of RedHill Biopharma Inc. & Director Comp: $469.8kMs. Alexandra OkmianSenior Business Development & Investor Relations ManagerDr. Reza Fathi Ph.D. (Age 69)Senior Vice President of Research & Development Comp: $299.29kMr. Guy Goldberg J.D. (Age 48)Chief Business Officer Comp: $338.13kDr. June S. Almenoff FACP (Age 67)M.D., Ph.D., Chief Medical Officer Ms. Patricia Anderson B.Sc. RACSenior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsEdesa BiotechNASDAQ:EDSAFSD PharmaNASDAQ:HUGEOragenicsNYSE:OGENImunonNASDAQ:IMNNPieris PharmaceuticalsNASDAQ:PIRSView All CompetitorsInstitutional OwnershipGagnon Securities LLCBought 28,771 shares on 5/14/2024Ownership: 0.398%View All Institutional Transactions RDHL Stock Analysis - Frequently Asked Questions How have RDHL shares performed in 2024? RedHill Biopharma's stock was trading at $1.46 on January 1st, 2024. Since then, RDHL shares have decreased by 68.3% and is now trading at $0.4628. View the best growth stocks for 2024 here. When is RedHill Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, June 10th 2024. View our RDHL earnings forecast. How were RedHill Biopharma's earnings last quarter? RedHill Biopharma Ltd. (NASDAQ:RDHL) released its quarterly earnings data on Tuesday, November, 30th. The biotechnology company reported ($20.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($19.20) by $0.80. The biotechnology company had revenue of $21.61 million for the quarter, compared to the consensus estimate of $23.41 million. During the same quarter last year, the business earned ($20.00) earnings per share. When did RedHill Biopharma's stock split? Shares of RedHill Biopharma reverse split on the morning of Thursday, March 23rd 2023. The 1-40 reverse split was announced on Thursday, March 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of RedHill Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA). Who are RedHill Biopharma's major shareholders? RedHill Biopharma's stock is owned by many different retail and institutional investors. Top institutional investors include Gagnon Securities LLC (0.40%). How do I buy shares of RedHill Biopharma? Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RDHL) was last updated on 5/26/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaWARNING about the death of the U.S. dollar…Colonial MetalsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsBuy this small stock before coming AI Tidal WaveChaikin Analytics$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading AcademyElon’s New Device is About to Shock the WorldInvestorPlaceNew Options need New Trading StrategiesNetpicksWrite this ticker symbol down…StocksToTrade Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RedHill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.